Results of the treatment of bone metastases with modular prosthetic replacement—analysis of 67 patients by unknown
Guzik Journal of Orthopaedic Surgery and Research  (2016) 11:20 
DOI 10.1186/s13018-016-0353-6RESEARCH ARTICLE Open AccessResults of the treatment of bone
metastases with modular prosthetic
replacement—analysis of 67 patients
Grzegorz GuzikAbstract
Background: Surgical treatment of long-bone metastases requires a comprehensive approach. The indications
for surgery are based on the patient’s general condition, type and stage of cancer, and survival time expectancy.
Tumor modular endoprostheses have been increasingly used. Surgery should provide pain relief and improve the
quality of life.
Methods: Between 2010 and 2013, 67 patients with malignant metastases were surgically treated with resection
prostheses. We performed a retrospective analysis of the indications for the surgery, its course, the type of the
prostheses used, and the implantation techniques applied. We evaluated the most important clinical parameters
influencing the postoperative quality of life of the patients.
Results: Breast, prostate, and lung cancers are the most common primary tumors that metastasize to bones. The
most common site of the lesions is the proximal femur; sporadically, they do occur in bones distal to the knee and
elbow. After the surgery, all the patients could walk, most of them without crutches. The pain, rated on a VAS scale,
decreased significantly, and the Karnofsky score improved. We observed that joint mobility and the strength of the
muscles in the limbs allowed for normal functioning. Postoperative complications including infections and local
tumor recurrences were rarely observed.
Conclusions: The use of modular prostheses is an adequate method of treatment in patients with bone
metastases. A radical resection of the tumor, which prevents local recurrences and loosening of implants, gives
good outcomes. Reduced joint mobility resulting from muscle attachment cutting is well tolerated and concerns
mainly patients that underwent operations on the humerus.
Keywords: Bone metastases, Bone tumor resection, Postresectional bone alloplasty, Modular prostheses, Bone
radiotherapyBackground
A significant progress in oncology has resulted in the
prolonged survival of patients with myeloma as well as
breast, prostate, kidney, and thyroid cancer, but the inci-
dence of bone metastasis has risen. Most patients with
bone metastases need a combination of surgical and
oncological treatment. The disease is associated with
general bad condition, pain, reduced mobility, trouble
walking and working, and problems with independent
functioning. Often, the patients have to give up theirCorrespondence: grzegorz.guzik@vp.pl
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case of large, lytic tumors posing a risk of pathological
fractures and the already existing fractures, radiotherapy
is ineffective [1–3].
Bone metastases most commonly affect the axial skel-
eton involving the vertebral column, ribs, pelvis, and the
proximal femur and humerus. In most cases of bone
metastases, bone resorption and formation processes
coexist. The predominance of one process over the other
determines the type of metastasis. Sclerotic lesions, al-
most exclusively arising from the prostatic carcinoma,
are rarely an indication for surgical treatment. Lytic and
mixed metastases occur most frequently and pose a riskributed under the terms of the Creative Commons Attribution 4.0 International
by/4.0/), which permits unrestricted use, distribution, and reproduction in any
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bones [1, 3, 4].
It is very important to perform the surgery before frac-
ture occurs. Standard radiograms provide sufficient in-
formation about the structure of the bone and the risk
of a pathological fracture which is quantified in Mirel’s
scoring system. In the case of the involvement of the
vertebral column or the pelvis, CT scans and MRI prior
to the surgery are recommended for the more precise
evaluation of the extent of the lesions and thus appropri-
ate planning of the surgery [1, 5].
The qualification for surgery should be multifaceted
with account being taken of the age of the patient, gen-
eral condition and the type, staging, and grading of can-
cer. Patients in poor general condition and with poor
survival prognosis are referred for palliative care. In such
cases, it is usually agreed not to perform metastatic
tumor resection but to stabilize the fracture, which is
followed by radiotherapy. Patients with better prognoses
undergo resections of the metastatic tumor, which sig-
nificantly decrease pain and reduce the risk of local
recurrences. The use of tumor endoprosthesis should
provide effective and fast pain relief, early mobilization,
and longer implants survival. However, the use of
megaprostheses has some drawbacks, such as a high
risk of infections arising in surgical wounds and re-
duced functions of the limbs due to damaged muscle
attachments [1, 6–8].Methods
Over the period 2010–2013 at the Orthopaedic Depart-
ment in Brzozów, 67 long-bone metastatic tumor resec-
tions combined with modular prostheses implantations
were performed. The implants used at our department
were GMRS, Stryker (28) and MUTARS, Implantcast (39).
We analyzed the medical records of the patients with
special attention being given to the type and the stage of
cancer, the duration of the disease, the type of treatment,
and the prognosis. What was also assessed was the gen-
eral condition of the patients, the location and the inten-
sity of pain rated by VAS, Karnofsky performance status
score in patients, their joint mobility and ability to move,
and the provided orthopedic equipment. Before the sur-
gery, radiographic examinations in two projections were
conducted. In the cases of particularly large or histo-
pathologically unconfirmed tumors, we carried out CT
and MRI scans of the involved regions to assess the size
and location of the tumor, bone tissue, and cortical layer
condition as well as the involvement of the medullary
cavity. No vascular angiography of the tumor was per-
formed. The analysis of preoperative imaging tests
always involved precise planning of the surgical ap-
proach and the evaluation of the extent of bone and softtissue resection. Tumor resections were made with a
wide margin just like in the cases of primary bone tu-
mors. After the surgery, we assessed the intensity of pain
with VAS as well as the limb vasculature and innerv-
ation. Rehabilitation records were reviewed considering
the time when the walking and postoperative kinesither-
apy was started and the provided orthopedic equipment.
The passive and active range of joint motion was evalu-
ated 14 days and 3 months after the surgery. We also
considered the efficiency of different muscle groups,
pain intensity, and the Karnofsky performance status
score in patients. On the second, the 14th day, and
3 months after the surgery, radiographic signs were
analyzed in the context of the risk associated with re-
currence or implant loosening. The patients are under
the medical care of orthopedists with follow-up visits
repeated at 3-month intervals. The research has been
performed in accordance with the declaration of
Helsinki. As this retrospective analysis consists of
anonymised clinical routine data, the Research Ethics
Committee (Okręgowa Izba Lekarska in Crakov, ul
Krupnicza ) deems the application for and issue of an
Ethics approval not necessary. All the patients gave a
written consent to the use of data for research.
Results
Most patients (41) were women, and 26 were men. The
average age of women was 67, and of men 69. The mean
length of the monitoring period was 2.3 years (range
3.6–1.4 years). So far, 21 patients have died. Patho-
logical fractures were diagnosed in 61 patients. In six
patients, the size of the metastasis suggested a high risk
of a fracture. In all the patients with no detected frac-
tures, the lesions involved the proximal area of the
femur. Lytic lesions were noted in 66 cases (Fig 1), and
a sclerotic lesion in one case. Large soft tissue tumors
were diagnosed in 52 patients.
The incidence of primary cancers presented itself as
follows: breast cancer (32 patients), myeloma (12 patients),
kidney cancer (11 patients), bowel cancer (2 patients), thy-
roid cancer (2 patients), lung cancer (2 patients), prostate
cancer (1 patient), and cancer of unknown primary site (5
cases). The patients in whom the pathological fracture was
the first symptom of neoplastic disease underwent biopsy
and the surgery was postponed until its results were ob-
tained (Fig 2). In all the five cases, the histopathological
examination confirmed the metastatic bone tumor. With
regard to the diagnosis, kidney cancer was detected in two
cases, and lung cancer in one case. In the remaining
two cases, it was not possible to precisely determine the
primary site of the neoplasm which revealed itself as
adenocarcinoma in the histopathological analysis (Table 1).
The implanted prostheses included: 2 total humerus
prostheses, 7 proximal humerus prostheses, 45 proximal
Fig. 1 Typical indications for modular endoprosthetic replacement in
the distal femur. Bone destruction by metastatic breast carcinoma (a, b)
and radiograph of the modular endoprosthetic replacement (c)
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prostheses, and 5 proximal tibia prostheses (Table 2).
The preoperative general condition of the majority of the
patients was relatively good. Naturally enough, the Karnofsky
scores and the VAS scores varied from patient to pa-
tient, depending on the site of the metastases (Table 3).Patients with fractures of the lower extremity were not
able to walk. The position of the limb was forced, and
the presence of various deformities was detected (shorten-
ing, bent axis, thickened contour). Any attempts at moving
resulted in a strong pain. No symptoms of ischemia or
damage to peripheral nerves were detected. six patients
with extensive lytic lesions in the lower limb were walking
with the support of walking frames. The mobility of joints
was reduced due to pain. Attempts made in a lying position
at lifting the leg above the bed and extending the knee
caused pain or were impossible. Metastases in the upper
extremity did not affect the patients’ ability to walk. The pa-
tients were immobilized in Dessault vests or plaster splints.
Also in this group, symptoms of ischemia or damage to
peripheral nerves were not observed (Fig 3).
Bone and soft tissue resections were wide margin. There
was no need to perform large vessel or nerve resections,
with an exception of four patients with the axillary nerve
situated in the tumor area. In any of the patients, the can-
cer did not infiltrate the skin, so it was not necessary to
perform excision followed by reconstruction with flaps.
The extent of bone resections ranging from the minimum
of 6 cm in the humerus and the tibia and the maximum of
22 cm in the femur is shown below (Table 4).
In the postoperative period, a significant improvement
in the quality of life was reported by all the patients as a
result of reduced pain or its complete regression. The
mean pain intensity score by VAS in patients after lower
extremity surgeries was 3.8 and 3.1 in patients after
upper extremity surgeries. The mean Karnofsky perform-
ance score was 65 in patients after lower extremity surger-
ies and 75 in patients after upper extremity surgeries.
In a group of 58 patients with metastases to lower
extremities, 12 have been walking normally without the
support of crutches. Those are the patients with implants
in the following regions: the proximal area of the femur (6
patients), the distal area of the femur (5 patients), and the
proximal area of the tibia (1 patient). Thirty-nine patients
have been using only one crutch or stick when walking
longer distances, while seven patients have been walking
with both crutches.
In each patient, a significant decrease in the strength
of muscles in the operated extremity was observed. The
postoperative passive joint mobility was relatively good,
but active joint mobility was significantly reduced in the
patients who underwent the surgery of the arm. The
mean flexion of the arm was 70°, the mean extension
47°, internal rotation achieved 30°, and external 15° of
movement. Trendelenburg’s sign was clearly positive in
patients after femur surgeries which was indicative of
gluteal muscle dysfunction. The patients were able to
manage the stairs either alternating feet (47 patients) or
reverting to each step (11 patients). We observed no
contractures of a knee joint which normally cause trouble
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Fig. 2 Radiographs of proximal femur destruction by metastatic
renal cancer (a) and modular endoprosthetic replacement (b)
Guzik Journal of Orthopaedic Surgery and Research  (2016) 11:20 Page 4 of 9getting up from a chair or make it impossible. The loss of
range of knee motion was observed as extension deficit to
10° and flexion to 40°. During each of the proximal tibia
resections, the patellar ligament was sutured to a reversed
flap obtained from the medial head of the triceps muscle.
The limb was immobilized in a brace for 6 weeks, and














































Table 3 Mean scores of pain intensity level rated by a VAS scale
(mm) and the patients’ performance status level rated by a
Karnofsky scale in relation to the location of the metastases
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Fig. 3 Radiographs of proximal humerus destruction by myeloma
(a) and modular endoprosthetic replacement (b)
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sion range of motion was achieved.
No pathological fractures occurred in the same bone
during the hospitalization. Complications involving loos-
ening of an implant occurred in one patient (a case sum-
marized below). Operative wound revision was necessary
in two patients. The wounds were cleared from the
granulation tissue, irrigated with BETADINE Solution,
and the Garamycin sponge was implanted. Intraoperative
evaluations were culture-negative. The wounds healed
without further complications. Operative prosthesis revi-
sion was required in one case and simultaneous implant-
ation of a new prosthesis was performed. The surgical
wound healed by primary intention within 2 weeks after
the revision procedure. In the remaining three cases,
minor surgical wound infections were treated with intra-
venous antibiotic therapy without surgical intervention.
No thromboembolic complications were observed. In one
patient with renal clear-cell carcinoma, a massive local re-
currence of the neoplasm occurred in the thigh 3 months
after the surgery. The patient died after 5 months (Fig. 4).
In three other patients, minor local recurrences occurred.
The patients were referred for palliative radiotherapy which
resulted in the stability of the disease confirmed by the
radiological examination. No dislocations of the prostheses
were noted. One patient required LUMIC prosthesis im-
plantation due to acetabular fracture after falling down.
Discussion
Conventional osteosynthesis (fixation with an intramedul-
lary nail or plates with or without bone cement) have rep-
resented a common option for surgical management of
metastatic lesions [9–11]. Another possible choice of
treatment that has been increasingly used is modular
prostheses due to possibly long survival time in patients
with myeloma and other metastatic cancers (breast, pros-
tate, kidney, bowel, or thyroid cancer) [12–17].
With the progress in oncology, a significant number of
malignant cancers, particularly those metastasizing to
bones, have become chronic [18–21]. Technological de-
velopments in other fields, including material science,
anesthesiology and surgical techniques, have made it
possible to use large prostheses with an acceptable riskof complications. Materials used in a manufacturing
process are increasingly better and biocompatible; there-
fore, the incidence of allergic reactions and intolerance
symptoms has been lower. The comparisons of various
surgical treatment options, osteosynthesis (with or without
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the superiority of the latter as presented in literature
(Fig 5) [18, 20, 21].
The survival rate of the patients with modular pros-
theses after radical resections of metastatic tumors is
higher when compared to the patients that underwent
outdated standard treatment. The overall survival rate is
sometimes as high as 37 months, which obviously varies
in different cases, depending on the type of cancer, the
grade of malignancy, the stage of the disease, and the
methods of treatment [19–22].Fig. 4 Chronologically arranged radiograms of kidney cancer metastases to
prosthesis implantation (b). Next, the radiogram (c) shows the postoperativ
large tumor involving the whole thigh. There is visible damage to the femuMost studies have found that treatment results are better
in cases where pathological fractures have never occurred
which result from an easier technique of resection and a
lower incidence of recurrences. Thus, it is recommended to
perform a surgery in all the cases where metastases posing
a risk of fracture were diagnosed. Clinical and radiological
criteria for determining the risk of pathological fracture are
now widely known. It should be kept in mind that a par-
ticularly high risk is associated with bones subject to heavy
loading (the femur, the tibia, and the vertebral column)
[18, 21, 23]. The recurrence rate in patients after long-bone
metastatic tumor resections ranges from 4 to 28 %. The most
important objective seems to be a wide margin with a cuff of
healthy tissues which is a condition necessary for effective
treatment [6, 8, 21, 22, 24].
One should consider the possibilities of adjuvant treat-
ment, especially the use of radiation therapy and bispho-
sphonates. In the past, radiotherapy was a method of
choice in treating bone metastases, particularly to the spine
and the pelvis. Currently it is important as a method of
reducing pain in 50–85 % of patients as well as redu-
cing the incidence of local recurrences after surgeries.
Bisphosphonates are also effective in pain reduction, and
they significantly reduce the number of pathologicalthe proximal femur (a) after resection of bone tumor and modular
e recurrence of the disease. A coronal view from an MRI (d) shows a
r and a loose prosthesis
Fig. 5 Failed fixation (gamma nail with PMMA) of a proximal
femoral fracture due to breast cancer metastasis (a) and radiographs
after modular endoprosthesis replacement (b)
Fig. 6 Radiographs of proximal humerus destruction by metastatic breast c
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the treatment of metastatic breast cancer, prostate cancer,
and multiple myeloma) [4, 6, 7, 25].
In the case of the metastases of kidney cancer, thyroid
cancer, and myeloma, a trans-arterial embolization (TAE)
can be performed. This procedure limits vascularization of
the tumor, which results in a twofold or even threefold
reduction in bleeding during the surgery, and the oper-
ation time is reduced by about 25 %. Many authors have
confirmed the effectiveness of this treatment method in
reducing pain and number of local recurrences after resec-
tion of the tumor. Reduced intraoperative bleeding allows
for more precise preparation of tissues and resection of
lesions. According to some authors, embolization in-
creases the sensitivity of tumor cells to chemotherapy and
radiation therapy. We have not performed preoperative
embolization of tumors localized in the extremities at our
department. This procedure has been performed exclu-
sively when the tumor was localized in the pelvis and the
spine [26–28].
The indications for amputation due to cancer metastases
are extremely rare. It is performed in the case of large
metastatic tumors infiltrating the vascular and nerve
trunks or skin when limb-salvage treatment is not pos-
sible. An indication for amputation may be extensive
inflammation of bone and soft tissues that is localized
within the site of a former prosthetic implantation and
which is impossible to treat [2, 3, 18].
The present study clearly indicates that most metasta-
ses occur in the proximal area of the femur. Metastases
in other sites are less frequent; very rarely do they occur
in the area below the elbow or knee joint. Breast cancer
is the most metastatic (Fig 6). Prostate cancerancer (a) and after modular endoprosthetic replacement (b)
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cal treatment because of a relatively low risk of a
fracture.
Most common complications that may follow modular
alloplasty are surgical wound infections [29, 30]. Patients
constitute a group at the highest risk of infectious and
thromboembolic complications because the surgeries are
most often urgent, therefore, MRSA screening or other
pathogen detection tests are rarely carried out. There
are no clear recommendations as to the routine local
antibiotic therapy in the case of primary resection allo-
plasty. A rate of infectious complications ranges between
1.2 and 19.5 %. Preoperative radiotherapy is seen as one
of the major risk factors for developing infections. Major
risk factors include: decreased immunity as a result of
neoplastic disease and chemotherapy, wide surgical
approach with significant blood loss, and the size of
metal implants. Worse still, the patients are usually eld-
erly and with various general health problems.
Other potential complications include dislocation or
loosening of the implants and periprosthetic fractures.
Revision procedures are required in 3–17 % of patients
[31, 32].
The procedures concerning preparation and implant-
ation of GMRS and MUTARS prostheses differ. The
MUTARS prostheses allow for a smooth rotation of the
prosthesis stem. What is more, surgical management of
the bone marrow canal is carried out not by reaming,
but by rasping. The stems are bent, which minimizes the
risk of damaging the cortical bone while driving them.
The prostheses have a golden and silver coating, which
reduces the incidence of infectious complications and
allergic reactions.
Functional results of modular alloplasty are satisfac-
tory, especially in patients after proximal and distal
femur resections. Decreased gluteal muscles function
was not a big problem to patients. Most of the patients
walk efficiently without crutches. A slight limb length
discrepancy was not noticed by the patients and did
not affect their walking. The quality of life of the patients
after metastasis resections and implantations of modu-
lar prostheses improved significantly. The VAS and
Karnofsky scales showed clearly reduced pain and im-
proved functioning.
Conclusions
1. Modular tumor endoprosthesis may be an option in
surgical treatment of long-bone metastases providing
fast pain relief and early mobilization.
2. Radical metastatic tumor resection is a condition
necessary for a good treatment outcome. It prevents
local recurrences and damage to implant or its
loosening.3. Proximal humerus resections result in a reduced
shoulder mobility and weakening of muscle strength
which impair normal limb functions.
4. The incidence rate of infections in patients after
modular prostheses implantations varies. Efforts
should be directed at preventing infectious
complications because they are very difficult to treat.
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